Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Mayo Clinic Study of Aging U19

Award Number: U19AG102336
ORGANIZATION: NATIONAL INSTITUTE ON AGING
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/18/2026
PERIOD OF PERFORMANCE END DATE: 07/31/2031

Group Awards By:

View Award Description

Mayo Clinic Study of Aging U19 - ABSTRACT: Overall Clinical care in cognitive aging will take two major directions in coming years: Moving disease modifying treatments earlier in the disease course (to preclinical stages) and integration of diagnostic/prognostic blood- based biomarkers. Given that cognitive impairment is multifactorial, future treatments will require developing accessible biomarkers for each single etiological component of aging (e.g. Alzheimer’s disease [AD], Cerebrovascular disease [CeVD], TDP-43, alpha-synuclein) and providing tools to clinical workflows that can aid in guiding future therapies. The overall goal of Mayo Clinic Study of Aging (MCSA) is to use real-world settings to validate and deploy biomarkers in the community for cognitive aging. The MCSA established in 2004 through the funding of a U01 created a population-based, random sample in Olmsted County, MN presently with 2725 active participants, and has collected extensive longitudinal clinical, plasma, amyloid PET, tau PET, and MRI data. This new U19 grant will expand the efforts of our current U01 to a multi-site study that includes a newly established population-based sample in Mississippi (MCSA-MS) with about 500 currently active participants. In Aim 1, we will establish the U19 infrastructure for recruitment/retention of 5000 participants using the Administrative, Clinical, Biomarker, Neuroimaging, and Biostatistics and Data Coordinating Cores. In Aim 2, we will establish the MCSA Platform, a flexible and expandable approach, to test existing and emerging biomarkers to quantify multifactorial contributions to cognitive impairment. The MCSA Platform has two components: 1) Development of single-etiology staging schemes by considering various biomarkers for clinical utilization; and (2) Computing multi-etiology models of absolute lifetime risk of biological and clinical progression. These models will be a key factor in weighing risks and benefits of treatment when considering emerging treatments for cognitively unimpaired individuals. In Aim 2A, we will employ the MCSA platform in the U19 Project to evaluate accessible plasma AD staging and CeVD MRI biomarkers as multi compartmental predictors of cognitive progression/decline. In Aim 2B, we will establish readiness for evaluation of emerging TDP-43 and alpha- synuclein biomarkers as they become available using the MCSA Platform and infrastructure. Through Aim 3, we will provide broad access to MCSA data and samples to catalyze innovation and expedite progress in cognitive aging and dementia research. Through the robust infrastructure and the innovative MCSA Platform, the U19 grant will build the foundation to make important contributions to the field of cognitive aging and dementia, ultimately leading to better diagnostic tools, treatment planning, and patient care.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $4,496,369 )
2026	2026	MAYO CLINIC	200 1ST ST SW	ROCHESTER	MN	55905	OLMSTED	USA	Aging Research	000	1	8/18/2026	NEW	$4,496,369
														Subtotal = $4,496,369

Grand Total All Awards = $4,496,369

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Mayo Clinic Study of Aging U19

Award Number: U19AG102336

ORGANIZATION: NATIONAL INSTITUTE ON AGING

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/18/2026

PERIOD OF PERFORMANCE END DATE: 07/31/2031

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer